Suven Life Sciences has completed patient enrolment in its global Phase-3 clinical study of masupirdine for agitation associated with Alzheimer's dementia, randomizing 424 patients. The company expects topline results by May 2027.

Study overview

The multicenter, randomized, double-blind, placebo-controlled trial is being conducted across sites in the USA and Europe. The primary endpoint measures the change from baseline to Week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) items corresponding to the International Psychogeriatric Association (IPA) agitation criteria.

Key study details

The following table summarises the key parameters of the clinical study as disclosed:

Enrolment and timeline

The study was originally designed to randomize approximately 375 patients. However, because several patients were already undergoing screening when the initial target was reached, those who subsequently met all eligibility criteria were permitted to proceed to randomization. Consequently, a total of 424 patients were randomized into the study.

With enrolment now complete, the study advances to data collection. The last patient last visit is expected by end of December 2026, followed by a targeted database lock by end of March 2027.

Management perspective

Venkat Jasti, Chairman and Managing Director, stated that the strong enrolment highlights the significant unmet need for new treatment options for agitation associated with Alzheimer's disease. Ramakrishna Nirogi, President and Chief Scientific Officer, noted that masupirdine is a highly selective 5-HT6 receptor antagonist with a differentiated pharmacological profile, potentially addressing limitations of current sedative or antipsychotic treatments.

Suven Life Sciences shareholders approved all five resolutions placed before them at the company's 37th Annual General Meeting held on August 25, 2026. The meeting, conducted via Video Conferencing and Other Audio-Visual Means, saw strong participation from both promoter and public shareholders.

The agenda included ordinary business items such as the adoption of audited financial statements for FY26 and the reappointment of Prof. Seyed E Hasnain as a director liable to retire by rotation. Special business items focused on governance and capital structure adjustments.

Key Resolutions Passed

Shareholders voted in favor of all proposed resolutions with significant majorities. The voting process included remote e-voting from August 21 to August 24, 2026, followed by e-voting at the AGM.

Governance and Related Party Matters

A key special business item involved the approval of a related-party transaction regarding the appointment of Dr. Madhavi Jasti, Managing Director, to an office or place of profit in overseas wholly owned subsidiaries. Promoter group members abstained from voting on this resolution as required by regulations. Public shareholders approved the measure with 99.83% support.

Another special resolution sought shareholder approval for a variation in the utilization of funds raised through a preferential issue. This resolution received overwhelming support, with 99.98% of votes cast in favor.

Voting Participation

The company recorded high engagement from its shareholder base. Promoters holding 18.5 crore shares participated fully in the voting process for non-conflicted resolutions. Public institutional investors also showed strong participation, with over 88% of their outstanding shares polled for most resolutions.

The scrutinizer report confirmed that the entire voting process complied with Section 108 of the Companies Act, 2013, SEBI Listing Regulations, and relevant MCA circulars. All electronic data has been preserved for safekeeping as per statutory requirements.